The Trulicity pen -- an injectable drug for patients to manage their type 2 diabetes -- has been around for quite some time.

The trial conducted over 24 weeks, found that adding Trulicity to a existing SGLT2 treatment produced -1.34%, -1.21% for Trulicity 1.5 mg and 0.75 mg ... of less than 7% and less than or equal ...

Full year sales for Trulicity in 2016 were approaching $1 billion, compared with just over $3 billion for Victoza. The 40-week SUSTAIN 7 trial investigated the efficacy and safety of 0.5 mg ...